Which has better valuation & earnings, LNSR or CV?

CapsoVision has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.34 -$34.28M -$0.33 N/A CapsoVision $13.55M 24.34 -$25.32M -$0.47 N/A

Is LNSR or CV more profitable?

LENSAR has a net margin of 57.57% compared to CapsoVision's net margin of -214.74%. CapsoVision's return on equity of -177.85% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% CapsoVision -214.74% -177.85% -135.07%

Does the media prefer LNSR or CV?

In the previous week, CapsoVision had 1 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for CapsoVision and 2 mentions for LENSAR. LENSAR's average media sentiment score of 0.02 beat CapsoVision's score of -0.36 indicating that LENSAR is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LNSR or MOBI?

LENSAR has higher revenue and earnings than Mobia Medical. LENSAR is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.34 -$34.28M -$0.33 N/A Mobia Medical $32.04M 8.97 -$46.50M -$20.18 N/A

Is LNSR or MOBI more profitable?

LENSAR has a net margin of 57.57% compared to Mobia Medical's net margin of 0.00%. Mobia Medical's return on equity of 0.00% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Mobia Medical N/A N/A N/A

Does the media favor LNSR or MOBI?

In the previous week, Mobia Medical had 3 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Mobia Medical and 2 mentions for LENSAR. Mobia Medical's average media sentiment score of 0.34 beat LENSAR's score of 0.02 indicating that Mobia Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mobia Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TLSI or LNSR?

In the previous week, TriSalus Life Sciences had 4 more articles in the media than LENSAR. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 2 mentions for LENSAR. LENSAR's average media sentiment score of 0.02 beat TriSalus Life Sciences' score of -0.13 indicating that LENSAR is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ELMD or LNSR?

Electromed has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Electromed $73.78M 3.11 $5.15M $1.31 21.14 LENSAR $58.44M 1.34 -$34.28M -$0.33 N/A

Is ELMD or LNSR more profitable?

LENSAR has a net margin of 57.57% compared to Electromed's net margin of 11.34%. Electromed's return on equity of 15.71% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets Electromed 11.34% 15.71% 13.37% LENSAR 57.57% -529.08% 50.03%

LENSAR (LNSR) Competitors

$6.37 -0.08 (-1.24%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.38 +0.01 (+0.16%)

As of 10/9/2026 07:30 PM Eastern

Compare

LNSR vs. CV, MOBI, TMCI, TLSI, and ELMD

Should you buy LENSAR stock or one of its competitors? LENSAR's main competitors and comparable companies include CapsoVision (CV), Mobia Medical (MOBI), Treace Medical Concepts (TMCI), TriSalus Life Sciences (TLSI), and Electromed (ELMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does LENSAR compare to CapsoVision?

LENSAR (NASDAQ:LNSR) and CapsoVision (NASDAQ:CV) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

40.2% of LENSAR shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 2.3% of CapsoVision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

LENSAR has a net margin of 57.57% compared to CapsoVision's net margin of -214.74%. CapsoVision's return on equity of -177.85% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
CapsoVision	-214.74%	-177.85%	-135.07%

CapsoVision has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.34	-$34.28M	-$0.33	N/A
CapsoVision	$13.55M	24.34	-$25.32M	-$0.47	N/A

LENSAR has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, CapsoVision has a beta of -2.45, meaning that its stock price is 345% less volatile than the broader market.

In the previous week, CapsoVision had 1 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for CapsoVision and 2 mentions for LENSAR. LENSAR's average media sentiment score of 0.02 beat CapsoVision's score of -0.36 indicating that LENSAR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENSAR currently has a consensus target price of $11.33, indicating a potential upside of 77.92%. CapsoVision has a consensus target price of $9.50, indicating a potential upside of 44.16%. Given LENSAR's stronger consensus rating and higher probable upside, analysts plainly believe LENSAR is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

LENSAR beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does LENSAR compare to Mobia Medical?

LENSAR (NASDAQ:LNSR) and Mobia Medical (NASDAQ:MOBI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

In the previous week, Mobia Medical had 3 more articles in the media than LENSAR. MarketBeat recorded 5 mentions for Mobia Medical and 2 mentions for LENSAR. Mobia Medical's average media sentiment score of 0.34 beat LENSAR's score of 0.02 indicating that Mobia Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mobia Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENSAR has a net margin of 57.57% compared to Mobia Medical's net margin of 0.00%. Mobia Medical's return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Mobia Medical	N/A	N/A	N/A

LENSAR has higher revenue and earnings than Mobia Medical. LENSAR is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.34	-$34.28M	-$0.33	N/A
Mobia Medical	$32.04M	8.97	-$46.50M	-$20.18	N/A

40.2% of LENSAR shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LENSAR presently has a consensus target price of $11.33, indicating a potential upside of 77.92%. Mobia Medical has a consensus target price of $20.75, indicating a potential upside of 140.44%. Given Mobia Medical's stronger consensus rating and higher possible upside, analysts plainly believe Mobia Medical is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mobia Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Mobia Medical beats LENSAR on 8 of the 15 factors compared between the two stocks.

How does LENSAR compare to Treace Medical Concepts?

LENSAR (NASDAQ:LNSR) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 65.8% of LENSAR shares are owned by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, LENSAR had 1 more articles in the media than Treace Medical Concepts. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Treace Medical Concepts. LENSAR's average media sentiment score of 0.02 beat Treace Medical Concepts' score of 0.00 indicating that LENSAR is being referred to more favorably in the media.

Company	Overall Sentiment
LENSAR	Neutral
Treace Medical Concepts	Neutral

LENSAR has higher earnings, but lower revenue than Treace Medical Concepts. LENSAR is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.34	-$34.28M	-$0.33	N/A
Treace Medical Concepts	$212.69M	1.21	-$59M	-$0.93	N/A

LENSAR presently has a consensus target price of $11.33, indicating a potential upside of 77.92%. Treace Medical Concepts has a consensus target price of $5.17, indicating a potential upside of 30.89%. Given LENSAR's stronger consensus rating and higher possible upside, research analysts plainly believe LENSAR is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

LENSAR has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

LENSAR has a net margin of 57.57% compared to Treace Medical Concepts' net margin of -28.99%. Treace Medical Concepts' return on equity of -71.37% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

Summary

LENSAR beats Treace Medical Concepts on 11 of the 16 factors compared between the two stocks.

How does LENSAR compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

In the previous week, TriSalus Life Sciences had 4 more articles in the media than LENSAR. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 2 mentions for LENSAR. LENSAR's average media sentiment score of 0.02 beat TriSalus Life Sciences' score of -0.13 indicating that LENSAR is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENSAR	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TriSalus Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

TriSalus Life Sciences presently has a consensus target price of $10.20, indicating a potential upside of 151.23%. LENSAR has a consensus target price of $11.33, indicating a potential upside of 77.92%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

LENSAR has higher revenue and earnings than TriSalus Life Sciences. LENSAR is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A
LENSAR	$58.44M	1.34	-$34.28M	-$0.33	N/A

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

LENSAR has a net margin of 57.57% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
LENSAR	57.57%	-529.08%	50.03%

Summary

LENSAR beats TriSalus Life Sciences on 9 of the 16 factors compared between the two stocks.

How does LENSAR compare to Electromed?

Electromed (NYSE:ELMD) and LENSAR (NASDAQ:LNSR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

LENSAR has a net margin of 57.57% compared to Electromed's net margin of 11.34%. Electromed's return on equity of 15.71% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
LENSAR	57.57%	-529.08%	50.03%

In the previous week, LENSAR had 2 more articles in the media than Electromed. MarketBeat recorded 2 mentions for LENSAR and 0 mentions for Electromed. Electromed's average media sentiment score of 1.84 beat LENSAR's score of 0.02 indicating that Electromed is being referred to more favorably in the media.

Company	Overall Sentiment
Electromed	Very Positive
LENSAR	Neutral

Electromed has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.11	$5.15M	$1.31	21.14
LENSAR	$58.44M	1.34	-$34.28M	-$0.33	N/A

Electromed presently has a consensus target price of $43.75, indicating a potential upside of 58.00%. LENSAR has a consensus target price of $11.33, indicating a potential upside of 77.92%. Given LENSAR's higher probable upside, analysts plainly believe LENSAR is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Electromed has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market. Comparatively, LENSAR has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

40.8% of Electromed shares are owned by institutional investors. Comparatively, 40.2% of LENSAR shares are owned by institutional investors. 11.0% of Electromed shares are owned by company insiders. Comparatively, 65.8% of LENSAR shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Electromed beats LENSAR on 10 of the 16 factors compared between the two stocks.

Get LENSAR News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNSR vs. The Competition

Export

Metric	LENSAR	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79.24M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-19.30	25.57	274.15	26.16
Price / Sales	1.34	83.25	635.98	112.53
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	-2.92	5.93	11.21	6.34
Net Income	-$34.28M	$146.18M	$3.50B	$381.90M
7 Day Performance	-5.63%	-0.38%	-0.90%	-1.41%
1 Month Performance	-20.87%	-2.02%	-4.44%	-3.48%
1 Year Performance	-46.43%	5.08%	6.96%	1.16%

LENSAR Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNSR LENSAR	2.1458 of 5 stars	$6.37 -1.2%	$11.33 +77.9%	-46.9%	$79.24M	$58.44M	N/A	150	News Coverage
CV CapsoVision	3.2759 of 5 stars	$6.56 -1.9%	$9.50 +44.8%	+42.0%	$329.61M	$13.89M	N/A	99
MOBI Mobia Medical	3.7794 of 5 stars	$9.13 +1.2%	$20.75 +127.3%	N/A	$303.95M	$45.28M	N/A	167	Short Interest Increase
TMCI Treace Medical Concepts	2.4523 of 5 stars	$4.57 -1.0%	$5.17 +13.1%	-34.5%	$292.66M	$205.31M	N/A	450
TLSI TriSalus Life Sciences	2.2525 of 5 stars	$4.37 +2.8%	$10.20 +133.4%	-8.1%	$268.80M	$45.15M	N/A	102

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNSR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENSAR (LNSR) Competitors

LNSR vs. CV, MOBI, TMCI, TLSI, and ELMD

How does LENSAR compare to CapsoVision?

Summary

How does LENSAR compare to Mobia Medical?

Summary

How does LENSAR compare to Treace Medical Concepts?

Summary

How does LENSAR compare to TriSalus Life Sciences?

Summary

How does LENSAR compare to Electromed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENSAR (LNSR) Competitors

LNSR vs. CV, MOBI, TMCI, TLSI, and ELMD

How does LENSAR compare to CapsoVision?

Do institutionals & insiders have more ownership in LNSR or CV?

Is LNSR or CV more profitable?

Which has better valuation & earnings, LNSR or CV?

Which has more volatility & risk, LNSR or CV?

Does the media prefer LNSR or CV?

Do analysts recommend LNSR or CV?

Summary

How does LENSAR compare to Mobia Medical?

Does the media favor LNSR or MOBI?

Is LNSR or MOBI more profitable?

Which has higher valuation & earnings, LNSR or MOBI?

Do institutionals & insiders have more ownership in LNSR or MOBI?

Do analysts prefer LNSR or MOBI?

Summary

How does LENSAR compare to Treace Medical Concepts?

Do insiders and institutionals have more ownership in LNSR or TMCI?

Does the media prefer LNSR or TMCI?

Which has better valuation and earnings, LNSR or TMCI?

Do analysts rate LNSR or TMCI?

Which has more volatility & risk, LNSR or TMCI?

Is LNSR or TMCI more profitable?

Summary

How does LENSAR compare to TriSalus Life Sciences?

Does the media favor TLSI or LNSR?

Which has more volatility & risk, TLSI or LNSR?

Do analysts rate TLSI or LNSR?

Which has stronger valuation and earnings, TLSI or LNSR?

Do institutionals & insiders have more ownership in TLSI or LNSR?

Is TLSI or LNSR more profitable?

Summary

How does LENSAR compare to Electromed?

Is ELMD or LNSR more profitable?

Does the media favor ELMD or LNSR?

Which has higher valuation & earnings, ELMD or LNSR?

Do analysts recommend ELMD or LNSR?

Which has more risk & volatility, ELMD or LNSR?

Do insiders and institutionals have more ownership in ELMD or LNSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR vs. The Competition

LENSAR Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools